149 related articles for article (PubMed ID: 25674039)
1. Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis.
Wilson JM; Kunnimalaiyaan S; Kunnimalaiyaan M; Gamblin TC
Cancer Cell Int; 2015; 15(1):13. PubMed ID: 25674039
[TBL] [Abstract][Full Text] [Related]
2. MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest.
Wilson JM; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
J Surg Res; 2014 Oct; 191(2):280-5. PubMed ID: 24996256
[TBL] [Abstract][Full Text] [Related]
3. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma.
Koprowski S; Sokolowski K; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
J Surg Res; 2015 Oct; 198(2):434-40. PubMed ID: 25890434
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway.
Shi N; Yu H; Chen T
Onco Targets Ther; 2019; 12():7637-7647. PubMed ID: 31571914
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
6. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Narayan RS; Fedrigo CA; Brands E; Dik R; Stalpers LJ; Baumert BG; Slotman BJ; Westerman BA; Peters GJ; Sminia P
BMC Cancer; 2017 Mar; 17(1):204. PubMed ID: 28320338
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
8. [TNF-α activates PI3K/AKT pathway to promote proliferation of SW620
Dai L; Zhao X; Ma L; Li X; Zuo D; Li Y; Wei B; Sui Y; Xu F
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Jan; 36(1):33-41. PubMed ID: 32314722
[TBL] [Abstract][Full Text] [Related]
9. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
[TBL] [Abstract][Full Text] [Related]
10. Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy.
Sokolowski KM; Balamurugan M; Kunnimalaiyaan S; Wilson J; Gamblin TC; Kunnimalaiyaan M
Am J Surg; 2016 Apr; 211(4):755-60. PubMed ID: 26850133
[TBL] [Abstract][Full Text] [Related]
11. Compound C induces protective autophagy in human cholangiocarcinoma cells via Akt/mTOR-independent pathway.
Zhao X; Luo G; Cheng Y; Yu W; Chen R; Xiao B; Xiang Y; Feng C; Fu W; Duan C; Yao F; Xia X; Tao Q; Wei M; Dai R
J Cell Biochem; 2018 Jul; 119(7):5538-5550. PubMed ID: 29384220
[TBL] [Abstract][Full Text] [Related]
12. The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer.
Winder A; Unno K; Yu Y; Lurain J; Kim JJ
Cancer Biol Ther; 2017 Dec; 18(12):958-964. PubMed ID: 28112582
[TBL] [Abstract][Full Text] [Related]
13. GATA1 gene silencing inhibits invasion, proliferation and migration of cholangiocarcinoma stem cells via disrupting the PI3K/AKT pathway.
Shi G; Zhang H; Yu Q; Hu C; Ji Y
Onco Targets Ther; 2019; 12():5335-5354. PubMed ID: 31456644
[No Abstract] [Full Text] [Related]
14. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
[TBL] [Abstract][Full Text] [Related]
15. Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway.
Yang ZP; Zhao Y; Huang F; Chen J; Yao YH; Li J; Wu XN
World J Gastroenterol; 2015 Sep; 21(36):10385-99. PubMed ID: 26420965
[TBL] [Abstract][Full Text] [Related]
16. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
17. miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma.
Kang PC; Leng KM; Liu YP; Liu Y; Xu Y; Qin W; Gao JJ; Wang ZD; Tai S; Zhong XY; Cui YF
Cell Physiol Biochem; 2018; 49(5):1933-1942. PubMed ID: 30235453
[TBL] [Abstract][Full Text] [Related]
18. PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.
Qi L; Toyoda H; Xu DQ; Zhou Y; Sakurai N; Amano K; Kihira K; Hori H; Azuma E; Komada Y
Cancer Cell Int; 2015; 15():91. PubMed ID: 26421002
[TBL] [Abstract][Full Text] [Related]
19. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
20. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F
BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
